|
CN111278509A
|
|
TLR-9 agonists for modulating tumor microenvironment
|
|
EP3392345A1
|
|
Biomarker for small cell lung cancer therapy
|
|
GB201516676D0
|
|
Means for the treatment of HIV
|
|
LU92821B1
|
|
Combination comprising immunostimulatory oligonucleotides
|
|
US2015328308A1
|
|
Means for Eliciting an Immune Response and a Method Transfer
|
|
GB201402847D0
|
|
Covalently closed non-coding immunomodulatory DNA construct
|
|
GB201309657D0
|
|
Predictive biomarker for cancer therapy
|
|
GB201207476D0
|
|
pharmaceutical for the treatment of leishmaniasis
|
|
GB201021867D0
|
|
Non-coding immunomodulatory DNA construct
|
|
GB201021873D0
|
|
DNA expression construct
|
|
GB201014907D0
|
|
Use of a dumbbell-shaped DNA construct for the treatment of cancer through jet-injection administration
|
|
EP2246433A1
|
|
Concatamers for immune modulation
|
|
EP2058397A1
|
|
Multimere assembly for immunostimulation
|
|
KR20090012265A
|
|
Multimer for immunostimulation
|
|
BRPI0618907A2
|
|
dna expression construct, vector production method, vector production kit and expression construct production kit
|
|
AU2006289514A1
|
|
Functional in vitro immunoassay
|
|
US2009004703A1
|
|
Method for the Production of Suitable Dna Constructs for Specific Inhibition of Gene Expression by Rna Interference
|
|
WO2005039633A1
|
|
Agent for treating leishmania infections
|
|
WO2006015560A1
|
|
Immunomodulating agent used in conjunction with chemotherapy
|
|
CN1918293A
|
|
Substituted non-coding nucleic acid molecule for therapeutic or prophylaxis immunological stimulus for human and higher animal
|
